Laura Ley, Matthias E Liechti, Anna M Becker, Isabelle Straumann, Aaron Klaiber, Friederike Holze, Severin B Vogt, Denis Arikci, Yasmin Schmid
{"title":"参与迷幻药研究的动机和回顾性评价:一项健康志愿者的定性研究。","authors":"Laura Ley, Matthias E Liechti, Anna M Becker, Isabelle Straumann, Aaron Klaiber, Friederike Holze, Severin B Vogt, Denis Arikci, Yasmin Schmid","doi":"10.1007/s00213-025-06772-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively.</p><p><strong>Objectives: </strong>This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience again.</p><p><strong>Methods: </strong>This study used the data of 151 healthy volunteers who had ingested serotonergic psychedelics in one of six randomized, double-blind, placebo-controlled crossover trials at the same research site under similar conditions. The data were analyzed through qualitative content analysis.</p><p><strong>Results: </strong>The predominant motivations to participate in a trial were interest in psychedelics and an appealing setting. Expectations involved personal development and the occurrence of typical psychedelic effects. Hopes included transformative processes. The setting factors that promoted a positive experience were music and access to nature, whereas the sterile hospital environment was considered bothersome. Most participants valued the trusting relationship with their investigator. The most commonly criticized investigator characteristics were a perceived lack of support and investigator-induced psychological discomfort. Most participants considered their expectations exceeded and would take the study substances again, preferably in a setting in nature with friends.</p><p><strong>Conclusions: </strong>This paper identified four pivotal factors to be considered for psychedelic study experiences: (1) a secure interpersonal relationship, (2) an aesthetically pleasing environment, (3) access to nature, and (4) the use of music. This analysis reveals subjective views of volunteers in psychedelic Phase-I trials and may improve research standards.</p>","PeriodicalId":20783,"journal":{"name":"Psychopharmacology","volume":" ","pages":"1875-1892"},"PeriodicalIF":3.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296967/pdf/","citationCount":"0","resultStr":"{\"title\":\"Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.\",\"authors\":\"Laura Ley, Matthias E Liechti, Anna M Becker, Isabelle Straumann, Aaron Klaiber, Friederike Holze, Severin B Vogt, Denis Arikci, Yasmin Schmid\",\"doi\":\"10.1007/s00213-025-06772-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Rationale: </strong>Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively.</p><p><strong>Objectives: </strong>This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience again.</p><p><strong>Methods: </strong>This study used the data of 151 healthy volunteers who had ingested serotonergic psychedelics in one of six randomized, double-blind, placebo-controlled crossover trials at the same research site under similar conditions. The data were analyzed through qualitative content analysis.</p><p><strong>Results: </strong>The predominant motivations to participate in a trial were interest in psychedelics and an appealing setting. Expectations involved personal development and the occurrence of typical psychedelic effects. Hopes included transformative processes. The setting factors that promoted a positive experience were music and access to nature, whereas the sterile hospital environment was considered bothersome. Most participants valued the trusting relationship with their investigator. The most commonly criticized investigator characteristics were a perceived lack of support and investigator-induced psychological discomfort. Most participants considered their expectations exceeded and would take the study substances again, preferably in a setting in nature with friends.</p><p><strong>Conclusions: </strong>This paper identified four pivotal factors to be considered for psychedelic study experiences: (1) a secure interpersonal relationship, (2) an aesthetically pleasing environment, (3) access to nature, and (4) the use of music. This analysis reveals subjective views of volunteers in psychedelic Phase-I trials and may improve research standards.</p>\",\"PeriodicalId\":20783,\"journal\":{\"name\":\"Psychopharmacology\",\"volume\":\" \",\"pages\":\"1875-1892\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296967/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00213-025-06772-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00213-025-06772-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.
Rationale: Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively.
Objectives: This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience again.
Methods: This study used the data of 151 healthy volunteers who had ingested serotonergic psychedelics in one of six randomized, double-blind, placebo-controlled crossover trials at the same research site under similar conditions. The data were analyzed through qualitative content analysis.
Results: The predominant motivations to participate in a trial were interest in psychedelics and an appealing setting. Expectations involved personal development and the occurrence of typical psychedelic effects. Hopes included transformative processes. The setting factors that promoted a positive experience were music and access to nature, whereas the sterile hospital environment was considered bothersome. Most participants valued the trusting relationship with their investigator. The most commonly criticized investigator characteristics were a perceived lack of support and investigator-induced psychological discomfort. Most participants considered their expectations exceeded and would take the study substances again, preferably in a setting in nature with friends.
Conclusions: This paper identified four pivotal factors to be considered for psychedelic study experiences: (1) a secure interpersonal relationship, (2) an aesthetically pleasing environment, (3) access to nature, and (4) the use of music. This analysis reveals subjective views of volunteers in psychedelic Phase-I trials and may improve research standards.
期刊介绍:
Official Journal of the European Behavioural Pharmacology Society (EBPS)
Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:
Human Psychopharmacology: Experimental
This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.
Human Psychopharmacology: Clinical and Translational
This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.
Preclinical psychopharmacology: Behavioral and Neural
This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.
Preclinical Psychopharmacology: Translational
This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.
Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic
This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.